Lv1
80 积分 2025-08-18 加入
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2天前
已完结
Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma
7天前
已关闭
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
14天前
已完结
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
20天前
已完结
Risk-adaptive Therapy Guided by Dynamic ctDNA in Nasopharyngeal Carcinoma
21天前
已完结
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial
22天前
已完结
Artificial intelligence-based pathological model for pan-cancer lymph node metastasis detection: a multicentre diagnostic study with retrospective and prospective validation
22天前
已完结
Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
22天前
已完结
AI-based BRAIx risk score for the intermediate-term prediction of breast cancer: a population cohort study
22天前
已完结
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
22天前
已关闭
皖公网安备34019202002308
